Genetics of vasopressin receptors

Current Hypertension Reports

Volumn 6, Issue 1, 2004, Pages 21-26

  Thibonnier, Marc ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 2; ARGIPRESSIN RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CORTICOTROPIN; FOLLITROPIN RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LIPOPROTEIN RECEPTOR; MEMBRANE RECEPTOR; MICROSATELLITE DNA; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; PROOPIOMELANOCORTIN; RECEPTOR SUBTYPE; SR 121463B; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V3 RECEPTOR;

ARTICLE; ATHEROSCLEROSIS; CELL MEMBRANE PERMEABILITY; CLINICAL GENETICS; DRUG RECEPTOR BINDING; ENDOCRINE TUMOR; ENDOPLASMIC RETICULUM; ESSENTIAL HYPERTENSION; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC CODE; GENETIC LINKAGE; GENETIC TRAIT; GENETIC VARIABILITY; HEART FAILURE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MALE; MONOGENIC DISORDER; MOUSE; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; PATHOGENESIS; PHENOTYPIC VARIATION; PROTEIN DOMAIN; PROTEIN FAMILY; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS;

EID: 5444223755     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-004-0006-8     Document Type: Article

References (25)

1. Rana BK, Shiina T, Insel PA: Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. Annu Rev Pharmacol Toxicol 2001, 41: 593-624.
2. Clapham DE: Mutations in G protein-linked receptors: novel insights on disease. Cell 1994, 75:1237-1239.
3. Simonds WF: G protein-regulated signaling dysfunction in human disease. J Investig Med 2003, 51:194-214.
4. Thibonnier M, Coles P, Thibonnier A, Shoham M: The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 2001, 41:175-202.
5. Thibonnier M, Conarty DM, Preston JA, et al.: Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998, 449:251-276.
6. Bichet DG, Lonergan M, Arthus MF, et al.: Nephrogenic diabetes insipidus due to mutations in AVPR2 and AQP2. In Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research. Edited by Saito T, Kurokawa K, Yoshida S. Amsterdam: Elsevier Science; 1995:605-613.
7. Birnbaumer M: Mutations and diseases of G protein coupled receptors. J Recept Signal Transduct Res 1995, 15: 131-160.
8. Bichet DG, Oksche A, Rosenthal W: Congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 1997, 8: 1951-1958.
9. Oksche A, Rosenthal W: The molecular basis of nephrogenic diabetes insipidus. J Mol Med 1998, 76:326-337.
10. Morello JP, Bichet DG: Nephrogenic diabetes insipidus. Annu Rev Physiol 2001, 63:607-630.
11. Barak LS, Oakley RH, Laporte SA, Caron MG: Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci U S A 2001, 98:93-98.
12. Wilbanks AM, Laporte SA, Bohn LM, et al.: Apparent loss-of-function mutant GPCRs revealed as constitutively desensitized receptors. Biochemistry 2002, 41:11981-11989.
13. Morello JP, Salahpour A, Laperrière A, et al.: Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 2000, 105:887-895.
14. Tan CM, Nickols HH, Limbird LE: Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation. J Biol Chem 2003, 278:35678-35686.
15. Wersinger SR, Ginns EI, O'Carroll AM, et al.: Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol Psychiatry 2002, 7:975-984.
16. Arnaldi G, Gasc J, de Clauser E, Bertagna X: Variable expression of the V1 vasopressin receptor modulates the phenotypic response of steroid-secreting adrenocortical tumors. J Endocrinol Metab 1998, 83:2029-2035.
17. Mune T, Murase H, Yamakita N, et al.: Eutopic overexpression of vasopressin V1a receptor in adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2002, 87:5706-5713.
18. De Keyser Y, Lenne F, Auzan C, et al.: The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. J Clin Invest 1996, 97:1311-1318.
19. Dahia PL, Ahmed-Shuaib A, Jacobs RA, et al.: Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors. J Clin Endocrinol Metab 1996, 81:1768-1771.
20. Rene P, Grino M, Viollet C, et al.: Overexpression of the V3 vasopressin receptor in transgenic mice corticotropes leads to increased basal corticosterone. J Neuroendocrinol 2002, 14: 737-744.
21. Small KM, Tanguay DA, Nandabalan K, et al.: Gene and protein domain-specific patterns of genetic variability within the G-protein coupled receptor superfamily. Am J Pharmacogenomics 2003, 3:65-71.
22. Thibonnier M, Jeunemaitre X, Graves MK, et al.: Structure of the human V1a vasopressin receptor gene. In Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research. Edited by Saito T, Kurokawa T, Yoshida S. Amsterdam: Elsevier Science; 1995:553-571.
23. Thibonnier M, Graves MK, Wagner MS, et al.: Study of V(1)-vascular vasopressin receptor gene microsatellite polymorphisms in human essential hypertension. J Mol Cell Cardiol 2000, 32:557-564.
24. Kim SJ, Young LJ, Gonen D, et al.: Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism. Mol Psychiatry 2002, 7: 503-507.
25. Chen CH, Chen WY, Liu HL, et al.: Identification of mutations in the arginine vasopressin receptor 2 gene causing nephrogenic diabetes insipidus in Chinese patients. J Hum Genet 2002, 47: 66-73.